<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>31</volume><submitter>Nguyen CTT</submitter><pubmed_abstract>&lt;h4>Objectives&lt;/h4>The associations between the neutrophil-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) with the responses of non-small cell lung cancer (NSCLC) patients receiving immune checkpoint inhibitors (ICI) and the NLR/PLR predictive potential were evaluated via meta-analysis.&lt;h4>Methods&lt;/h4>A systematic review was conducted using the PubMed, Embase, and The Cochrane Library databases until October 2021. The relationship between NLR/PLR and overall survival (OS) and progression-free survival (PFS) was evaluated using pooled hazard ratios (HR). The relationship between NLR/PLR and overall response rate (ORR) and disease control rate (DCR) was assessed via pooled odds ratios (OR). Heterogeneity between studies, publication bias, subgroup and sensitivity analyses, tri</pubmed_abstract><journal>Cancer control : journal of the Moffitt Cancer Center</journal><pagination>10732748241285474</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11406641</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Predictability of Neutrophile to Lymphocyte Ratio and Platelet to Lymphocyte Ratio on the Effectiveness of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer patients: A Meta-Analysis.</pubmed_title><pmcid>PMC11406641</pmcid><pubmed_authors>Nguyen CTT</pubmed_authors><pubmed_authors>Huong PT</pubmed_authors><pubmed_authors>Van TNK</pubmed_authors></additional><is_claimable>false</is_claimable><name>Predictability of Neutrophile to Lymphocyte Ratio and Platelet to Lymphocyte Ratio on the Effectiveness of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer patients: A Meta-Analysis.</name><description>&lt;h4>Objectives&lt;/h4>The associations between the neutrophil-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) with the responses of non-small cell lung cancer (NSCLC) patients receiving immune checkpoint inhibitors (ICI) and the NLR/PLR predictive potential were evaluated via meta-analysis.&lt;h4>Methods&lt;/h4>A systematic review was conducted using the PubMed, Embase, and The Cochrane Library databases until October 2021. The relationship between NLR/PLR and overall survival (OS) and progression-free survival (PFS) was evaluated using pooled hazard ratios (HR). The relationship between NLR/PLR and overall response rate (ORR) and disease control rate (DCR) was assessed via pooled odds ratios (OR). Heterogeneity between studies, publication bias, subgroup and sensitivity analyses, tri</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Jan-Dec</publication><modification>2026-06-03T23:42:53.631Z</modification><creation>2025-04-04T11:33:53.851Z</creation></dates><accession>S-EPMC11406641</accession><cross_references><pubmed>39285591</pubmed><doi>10.1177/10732748241285474</doi></cross_references></HashMap>